AB0100 COMPARATIVE ANALYSIS OF THE EFFECTIVENESS AND TOLERANCE OF INTRA-ARTICULAR INJECTION OF PLATELET RICH PLASMA VS HYALURONIC ACID AND NON-ARTHROSCOPIC JOINT LAVAGE IN PATIENTSWITH KNEE OSTEOARTHRITIS

Background: Knee Osteoarthritis (KOA) is a common condition associated with pain and morbidity. The impact of this pathology makes it necessary to develop new procedures for joint regeneration. Regenerative treatments such as platelet-rich plasma (PRP) are being proposed as a safe alternative, capable of regenerating damaged tissues and improving the quality of life, reducing the need to surgical procedures (1-4). Objectives: To compare the effectiveness of PRP treatment vs Hialuronic Acid (HA) and Non-Arthroscopic Joint Lavage (NAJL) in patients with KOA. Methods: It was performed a prospective, 3-months observational study of 51 patients with KOA, from the OA clinic of the Reina Sofia Hospital of Cordoba. Patients were treated according to clinical practice in 1 of the 3 treatment arms (PRP, HA, NAJL). Pain and disability were evaluated using Visual Analogue Scale (VAS) of joint pain, WOMAC and OARSI. We compared the baseline data using simple ANOVA and chi-squared tests and the intra- and inter-group differences before and after treatment (0, 1 and 3 months) using the mixed ANOVA test. All comparisons were bilateral considering p≤0.05 as a significant result. Results: 51 patients were enrolled, of which 52.9% were female. The average age (±SD) was 58.47 ± 7.48 years. The average Body Mass Index (BMI) was 30.64 ± 4.25 Kg/m2. Characteristics at baseline were comparable among the 3 treatment groups (Table 1). An overall improvement was observed during the follow-up in the PRP group in terms of pain and disability with respect to the baseline, with a VAS MD of -3.00 [95% CI, -4.79 to -1.21] in the first month and -3.08 [CI 95%, -4.79 to -1.38] at 3 months (p Conclusion: Based on our results, the intra-articular infiltration with PRP could therefore constitute a safe and effective treatment option in KOA patients, with short-medium term results superior in terms of pain and disability to conventional treatment with HA and NALJ. Reference [1] Huang Y, et al. Orthopade. 2019 Jan 8. 2)Burke, et al. Clin trans Med (2016) 5-27. 3)Wroblewski AP, et al. Oper Tech Orthop 2010; 20: 98-105. 4) De La Mata J, et al. Reumatol Clinica. 2013; 9(3):166-71. Disclosure of Interests: Rafaela Ortega Castro: None declared, Rocio Segura: None declared, Jerusalem Calvo Gutierrez: None declared, Rocio Espino-Garcia: None declared, Maria del Carmen Castro Villegas Paid instructor for: MSD, Abbvie, Pfizer, Janssen, Lilly, Roche, Alejandro Escudero Contreras: None declared, Miguel A. Caracuel-Ruiz: None declared, Ladehesa Pineda Lourdes: None declared, Desiree Ruiz-Vilchez: None declared, Montserrat Romero-Gomez: None declared, Pilar Carreto-Font: None declared, Eduardo Collantes Estevez: None declared, Font Ugalde Pilar: None declared